DCPH - Deciphera Pharmaceuticals to raise $150M in stock and warrants offering.

Deciphera Pharmaceuticals (NASDAQ:DCPH) priced its underwritten public offering of 5.25M shares at $10/share. The company is also offering 9.75M shares at a purchase price of $9.99/pre-funded warrant. Underwriters granted 30-day option to purchase up to an additional 2.25M shares. Proceeds are expected tp be ~$150M; net proceeds to be used for continuing to fund the development of vimseltinib including in its pivotal Phase 3 MOTION study, additional clinical trials as well as clinical research outsourcing and manufacturing of clinical trial material, development of DCC-3116 including multiple Phase 1b combination studies and potential Phase 2 expansion combination cohorts in multiple tumor types. Offering is expected to close on Apr.29.

For further details see:

Deciphera Pharmaceuticals to raise $150M in stock and warrants offering.